Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGFBP3 | P17936 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908877 | 0.83 | GAA (0.50) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL975885 | 0.82 | IGFBP5 (0.43) | IGFBP3ALOX15ALDH1A1HIF1APTGS2 | |
| SCHEMBL11827386 | 0.81 | IGFBP5 (0.47) | IGFBP3ALOX15KDM4EALDH1A1HIF1A | |
| SCHEMBL2908985 | 0.81 | ALOX15 (0.48) | IGFBP3ALOX15KDM4EALDH1A1MAPT | |
| SCHEMBL2906699 | 0.80 | LCK (0.46) | IGFBP3ALOX15HIF1AIGFBP5TSHR | |
| SCHEMBL11823904 | 0.80 | IGFBP5 (0.46) | IGFBP3ALOX15KDM4EALDH1A1HIF1A | |
| SCHEMBL2908145 | 0.79 | DHODH (0.48) | IGFBP3ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL9039085 | 0.79 | ALDH1A1 (0.48) | ALOX15KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL4471851 | 0.79 | IGFBP5 (0.41) | IGFBP3ALOX15ALDH1A1HIF1AIGFBP5 | |
| SCHEMBL1305232 | 0.79 | ALDH1A1 (0.49) | IGFBP3ALDH1A1HIF1ACYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180136233-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | NESTEC S.A. (CH) | 2018-05-17 | — | — | US | disclosed |
| US-9891235-B2 | Pathway specific assays for predicting irritable bowel syndrome diagnosis | NESTEC S.A. (CH) | 2018-02-13 | — | — | US | disclosed |
| US-20170240652-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | NESTEC S.A. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170240652-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | NESTEC S.A. (CH) | 2017-08-24 | — | — | US | disclosed |
| WO-2016079708-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | NESTEC S.A. (CH) | 2016-05-26 | — | — | WO | disclosed |
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | NESTEC S.A. (CH) | 2016-05-12 | — | — | US | disclosed |
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | NESTEC S.A. (CH) | 2016-05-12 | — | — | US | disclosed |
| EP-1578423-B1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7176207-B2 | Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7084142-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-01 | — | — | US | disclosed |
| EP-1578423-A1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004052366-A9 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AG (DE) | 2005-06-23 | — | — | WO | disclosed |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| US-6861424-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052366-A1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | WO | disclosed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | IGFBP3 3464/4885ALOX15 789/4885KDM4E 4333/4885 |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | IGFBP3 3464/4885ALOX15 789/4885KDM4E 4333/4885 |
| US-20170240652-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | TPH1, HTR5A, KYNU | IGFBP3 1601/4885ALOX15 329/4885KDM4E 2415/4885 |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | TBXA2R, ADORA1, P2RY1 | IGFBP3 3914/4885ALOX15 1084/4885KDM4E 4372/4885 |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, TBXA2R, ADORA2B | IGFBP3 3531/4885ALOX15 763/4885KDM4E 4378/4885 |
| US-20180136233-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | FABP2, TPH2, TPH1 | IGFBP3 1292/4885ALOX15 123/4885KDM4E 4546/4885 |
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | FABP2, TPH2, TPH1 | IGFBP3 1292/4885ALOX15 123/4885KDM4E 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.